Mirela Raos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mirela Raos has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Branka Golubić Ćepulić
Clinical Department of Transfusion Medicine and Transplantation Biology, University Hospital Centre Zagreb, Zagreb, Croatia
2 shared publications I. Bojanić
Clinical Department of Transfusion Medicine and Transplantation Biology, University Hospital Centre Zagreb, Kišpatićeva 12, 10000 Zagreb, Croatia; University of Applied Health Sciences, Zagreb, Croatia; School of Medicine, University of Zagreb, Croatia
2 shared publicationsMarija Lukić
Department of Transfusion Medicine and Transplantation Biology University Hospital Center Zagreb Zagreb Croatia
2 shared publications- Milica Liker
Department of Transfusion Medicine and Transplantation Biology, University Hospital Centre Zagreb, Zagreb, Croatia
2 shared publications B. Golubić Ćepulić
Clinical Department of Transfusion Medicine and Transplantation Biology, University Hospital Centre Zagreb, Kišpatićeva 12, 10000 Zagreb, Croatia; University of Applied Health Sciences, Zagreb, Croatia; School of Medicine, University of Zagreb, Croatia; Department of Health Studies, University of Split, Croatia
1 shared publicationB.G. Ćepulić
Clinical Department of Transfusion Medicine and Transplantation biology, University Hospital Centre of Zagreb, Kišpatićeva 12, 10 000 Zagreb, Croatia; University of Applied Health Sciences of Zagreb, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, Croatia; Department of Health Studies, University of Split, Split, Croatia
1 shared publication
Latest Publications
- 27 May 2025
- Published by Wiley in Transfusion
- Vol. 65 (7) , 1319-1327
Uncommon RHD variants and an unconventional RHCE hybrid allele with D epitope expression in blood donors from northwestern Croatia
Background: Some D variants, especially those expressed by hybrid alleles, can react falsely negative in routine serology tests. Recently, an increasing number of facilities have strived to implement a method for RHD molecular screening in blood donors.Study Design and Methods: The participants in this two‐year prospective study were 735 unrelated voluntary blood donors from northwestern Croatia. Blood donors were individually tested for RHD sequences by qPCR. In reactive samples, D antigen was confirmed by adsorption/elution.Results: RHD screening was performed by examination of RHD exons 3, 5, and 10 in 589/704 (83.7%) serologically D‐negative ccee samples, all being negative. Serology results of the Rh phenotype (C+ and/or E+) were confirmed by qPCR in the remaining 115 donors (16.3%). In this group, 112 donors were RHD‐negative. RHD DEL alleles were determined in two Ccee donors (0.28%): RHD*DEL32 and RHD*DEL44. One donor (0.14%) was homozygous for RHD deletion but revealed an RHD sequence in 5′‐UTR within the RHCE locus, c.‐132A. All three donors with Rh variants expressed D epitopes as displayed by adsorption/elution. The serologically weak D group (31 participants) contained seven RHD alleles.Discussion: This study reports the DEL phenotype of RHD*DEL44 expression. The hybrid allele RHCE*D(1)‐CE was described previously, but here we illustrate the presence of D epitope(s) in a donor with homozygous RHD deletion. Weak D type 40 haplotype association was elucidated. Blood donor molecular Rh testing can prevent the immunization of genuine D‐negative patients by D‐positive units that reacted negatively in routine serological testing.
- 27 May 2025
- Published by Wiley in Transfusion
- Vol. 65 (7) , 1319-1327
Uncommon RHD variants and an unconventional RHCE hybrid allele with D epitope expression in blood donors from northwestern Croatia
Background: Some D variants, especially those expressed by hybrid alleles, can react falsely negative in routine serology tests. Recently, an increasing number of facilities have strived to implement a method for RHD molecular screening in blood donors.Study Design and Methods: The participants in this two‐year prospective study were 735 unrelated voluntary blood donors from northwestern Croatia. Blood donors were individually tested for RHD sequences by qPCR. In reactive samples, D antigen was confirmed by adsorption/elution.Results: RHD screening was performed by examination of RHD exons 3, 5, and 10 in 589/704 (83.7%) serologically D‐negative ccee samples, all being negative. Serology results of the Rh phenotype (C+ and/or E+) were confirmed by qPCR in the remaining 115 donors (16.3%). In this group, 112 donors were RHD‐negative. RHD DEL alleles were determined in two Ccee donors (0.28%): RHD*DEL32 and RHD*DEL44. One donor (0.14%) was homozygous for RHD deletion but revealed an RHD sequence in 5′‐UTR within the RHCE locus, c.‐132A. All three donors with Rh variants expressed D epitopes as displayed by adsorption/elution. The serologically weak D group (31 participants) contained seven RHD alleles.Discussion: This study reports the DEL phenotype of RHD*DEL44 expression. The hybrid allele RHCE*D(1)‐CE was described previously, but here we illustrate the presence of D epitope(s) in a donor with homozygous RHD deletion. Weak D type 40 haplotype association was elucidated. Blood donor molecular Rh testing can prevent the immunization of genuine D‐negative patients by D‐positive units that reacted negatively in routine serological testing.
- 11 February 2022
- Published by Wiley in Transfusion
- Vol. 62 (3) , 600-611
Changes in the incidence of transfusion reactions in hematological patients over the past 30 years
Background: Patients with hematological diseases are polytransfused and often immunocompromised, therefore susceptible to transfusion reactions (TR). This study aims to document the incidence of TRs in adult hematological patients and assess the effect of changes in the production of blood components and transfusion practice on their occurrence.Study design and methods: Retrospective observational analysis of TRs reported from 1993 to 2019 was performed. For the analysis of the effect of changes on the incidence of TRs, the evaluated time was divided into two periods: the 1st period before the introduction of changes in production, when leukoreduced blood components were used only selectively, and the 2nd period, when semi‐automated method of production and universal leukoreduction was introduced.Results: The decrease in the incidence of TRs was observed for both red blood cell (RBC) and platelet concentrate (PC) transfusions in the 2nd period. Since platelet additive solution has been used, a further decrease in the incidence was reported. The decrease in incidence was also observed for delayed hemolytic/serological transfusion reactions and for transfusion‐transmitted bacterial infections. Four cases of incorrect blood transfusions were uniquely related to the hematological patients, caused by antigen loss and transfusion ordering after ABO‐incompatible hematopoietic stem cell transplantation.Discussion: Our results provided evidence that the introduction of tools offered by modern transfusion medicine: universal leukodepletion, plasma replacement with additive solutions, sensitive laboratory techniques, prophylactic antigen matching policy, informatization, and automatization, decreased the incidence of TRs and improved transfusion safety.
- 11 February 2022
- Published by Wiley in Transfusion
- Vol. 62 (3) , 600-611
Changes in the incidence of transfusion reactions in hematological patients over the past 30 years
Background: Patients with hematological diseases are polytransfused and often immunocompromised, therefore susceptible to transfusion reactions (TR). This study aims to document the incidence of TRs in adult hematological patients and assess the effect of changes in the production of blood components and transfusion practice on their occurrence.Study design and methods: Retrospective observational analysis of TRs reported from 1993 to 2019 was performed. For the analysis of the effect of changes on the incidence of TRs, the evaluated time was divided into two periods: the 1st period before the introduction of changes in production, when leukoreduced blood components were used only selectively, and the 2nd period, when semi‐automated method of production and universal leukoreduction was introduced.Results: The decrease in the incidence of TRs was observed for both red blood cell (RBC) and platelet concentrate (PC) transfusions in the 2nd period. Since platelet additive solution has been used, a further decrease in the incidence was reported. The decrease in incidence was also observed for delayed hemolytic/serological transfusion reactions and for transfusion‐transmitted bacterial infections. Four cases of incorrect blood transfusions were uniquely related to the hematological patients, caused by antigen loss and transfusion ordering after ABO‐incompatible hematopoietic stem cell transplantation.Discussion: Our results provided evidence that the introduction of tools offered by modern transfusion medicine: universal leukodepletion, plasma replacement with additive solutions, sensitive laboratory techniques, prophylactic antigen matching policy, informatization, and automatization, decreased the incidence of TRs and improved transfusion safety.
- 1 February 2022
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 29 (1) , 37-43
Platelet transfusion practice and related transfusion reactions in a large teaching hospital
- 1 February 2022
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 29 (1) , 37-43
Platelet transfusion practice and related transfusion reactions in a large teaching hospital
- 8 August 2021
- Published by Wiley in Transfusion
- Vol. 61 (8) , 2516-2517
Monocyte monolayer assay predictions of clinical outcome for serologically incompatible red blood cells is all about timing
- 8 August 2021
- Published by Wiley in Transfusion
- Vol. 61 (8) , 2516-2517
Monocyte monolayer assay predictions of clinical outcome for serologically incompatible red blood cells is all about timing
- 1 May 2021
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 28 (2) , 186-190
Utilisation patterns of group O red blood cell transfusion by ABO and D non-identical recipients in large academic hospital
- 1 May 2021
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 28 (2) , 186-190
Utilisation patterns of group O red blood cell transfusion by ABO and D non-identical recipients in large academic hospital
- Open Access
- 30 October 2018
- Published by Zdravstveno veleuciliste in Journal of Applied Health Sciences
- Vol. 4 (2) , 179-186
Evaluation of antibody screening and identification pre-transfusion tests using DG Gel cards
- 30 October 2018
- Published by Zdravstveno veleuciliste in Journal of Applied Health Sciences
- Vol. 4 (2) , 179-186
Open AccessEvaluation of antibody screening and identification pre-transfusion tests using DG Gel cards